{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:12:36Z","timestamp":1781107956354,"version":"3.54.1"},"reference-count":59,"publisher":"Japanese Society for Pediatric Endocrinology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pediatr Endocrinol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1297\/cpe.28.59","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T18:03:44Z","timestamp":1563559424000},"page":"59-68","source":"Crossref","is-referenced-by-count":24,"title":["Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of          endocrine adverse events"],"prefix":"10.1297","volume":"28","author":[{"given":"Kenji","family":"Ihara","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Oita University Faculty of              Medicine, Yufu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"125","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kim,              R, Emi,                M, Tanabe,                K. Cancer            immunoediting from immune surveillance to immune escape.            Immunology          2007;121: 1\u201314.","DOI":"10.1111\/j.1365-2567.2007.02587.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Stewart,                TJ, Smyth,                MJ. Improving            cancer immunotherapy by targeting tumor-induced immune suppression.            Cancer Metastasis Rev          2011;30: 125\u201340.","DOI":"10.1007\/s10555-011-9280-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Postow,              MA, Callahan,                MK,              Wolchok,            JD. Immune            checkpoint blockade in cancer therapy. J Clin Oncol          2015;33: 1974\u201382.","DOI":"10.1200\/JCO.2014.59.4358"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Joshi,              K, Chain,                BM, Peggs,                KS,              Quezada,            SA. The            \u201cAchilles\u2019 heel\u201d of cancer and its implications for the development of novel            immunotherapeutic strategies. Cold Spring Harb Perspect            Med          2018;8: 8.","DOI":"10.1101\/cshperspect.a027086"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hodi,              FS, O\u2019Day,                SJ,                McDermott,              DF, Weber,                RW, Sosman,                JA, Haanen,                JB, et al.            Improved survival with ipilimumab in patients with metastatic            melanoma. N Engl J Med          2010;363: 711\u201323.","DOI":"10.1056\/NEJMoa1003466"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Brahmer,              J, Reckamp,                KL, Baas,                P, Crin\u00f2,                L,                Eberhardt,              WE,                Poddubskaya,              E, et al.            Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung            cancer. N Engl J Med          2015;373: 123\u201335.","DOI":"10.1056\/NEJMoa1504627"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ansell,              SM, Lesokhin,                AM,                Borrello,            I, Halwani,                A, Scott,                EC,                Gutierrez,              M, et al.            PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s            lymphoma. N Engl J Med          2015;372: 311\u20139.","DOI":"10.1056\/NEJMoa1411087"},{"key":"8","unstructured":"8. Powles,              T. Immune            checkpoint inhibitors for urologic cancer: the tip of the            iceberg? Eur Urol          2015;68: 280\u20132."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Topalian,                SL, Hodi,                FS,              Brahmer, JR,                Gettinger,              SN, Smith,                DC,                McDermott,              DF, et al.            Safety, activity, and immune correlates of anti-PD-1 antibody in            cancer. N Engl J Med          2012;366: 2443\u201354.","DOI":"10.1056\/NEJMoa1200690"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Merchant,                MS, Wright,                M, Baird,                K, Wexler,                LH,                Rodriguez-Galindo,              C, Bernstein,                D, et al.            Phase I clinical trial of ipilimumab in pediatric patients with advanced            solid tumors. Clin Cancer Res          2016;22: 1364\u201370.","DOI":"10.1158\/1078-0432.CCR-15-0491"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Park,              JA, Cheung,                NV.            Limitations and opportunities for immune checkpoint inhibitors in            pediatric malignancies. Cancer Treat Rev          2017;58: 22\u201333.","DOI":"10.1016\/j.ctrv.2017.05.006"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kabir,              TF, Chauhan,                A, Anthony,                L,                Hildebrandt,              GC. Immune            checkpoint inhibitors in pediatric solid tumors: status in 2018.            Ochsner J          2018;18: 370\u20136.","DOI":"10.31486\/toj.18.0055"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wedekind,                MF, Denton,                NL, Chen,                CY, Cripe,                TP. Pediatric            cancer immunotherapy: opportunities and challenges. Paediatr            Drugs          2018;20: 395\u2013408.","DOI":"10.1007\/s40272-018-0297-x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Corsello,                SM,                Barnabei,            A, Marchetti,                P, De                Vecchis, L,                Salvatori,              R, Torino,                F. Endocrine            side effects induced by immune checkpoint inhibitors. J Clin            Endocrinol Metab          2013;98: 1361\u201375.","DOI":"10.1210\/jc.2012-4075"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gonz\u00e1lez-Rodr\u00edguez,                E,                Rodr\u00edguez-Abreu,              D, Spanish Group            for Cancer Immuno-Biotherapy (GETICA). Immune checkpoint            inhibitors: review and management of endocrine adverse events.            Oncologist          2016;21: 804\u201316.","DOI":"10.1634\/theoncologist.2015-0509"},{"key":"16","unstructured":"16. Ntali,              G, Kassi,                E,                Alevizaki,              M. Endocrine            sequelae of immune checkpoint inhibitors. Hormones            (Athens)          2017;16: 341\u201350."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Girotra,              M, Hansen,                A, Farooki,                A, Byun,                DJ, Min,                L, Creelan,                BC, et al.            Investigational Drug Steering Committee (IDSC) Immunotherapy Task Force            collaboration. The current understanding of the endocrine            effects from immune checkpoint inhibitors and recommendations for            management. JNCI Cancer Spectr          2018;2: pky021.","DOI":"10.1093\/jncics\/pky021"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ishida,              Y, Agata,                Y,                Shibahara,              K, Honjo,                T. Induced            expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon            programmed cell death. EMBO J          1992;11: 3887\u201395.","DOI":"10.1002\/j.1460-2075.1992.tb05481.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Pauken,              KE, Wherry,                EJ.            Overcoming T cell exhaustion in infection and cancer.            Trends Immunol          2015;36: 265\u201376.","DOI":"10.1016\/j.it.2015.02.008"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Jain,              N, Nguyen,                H,              Chambers, C,                Kang,            J. Dual function            of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan            autoimmunity. Proc Natl Acad Sci USA          2010;107: 1524\u20138.","DOI":"10.1073\/pnas.0910341107"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Pedicord,                VA,                Montalvo,            W, Leiner,                IM,              Allison,            JP. Single dose            of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and            maintenance. Proc Natl Acad Sci USA          2011;108: 266\u201371.","DOI":"10.1073\/pnas.1016791108"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Robert,              C, Thomas,                L,                Bondarenko,              I, O\u2019Day,                S, Weber,                J, Garbe,                C, et al.            Ipilimumab plus dacarbazine for previously untreated metastatic            melanoma. N Engl J Med          2011;364: 2517\u201326.","DOI":"10.1056\/NEJMoa1104621"},{"key":"23","unstructured":"23. Comin-Anduix,                B,                Escuin-Ordinas,              H, Ibarrondo,                FJ.            Tremelimumab: research and clinical development.            Onco Targets Ther          2016;9: 1767\u201376."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Keir,              ME, Butte,                MJ,              Freeman, GJ,                Sharpe,            AH. PD-1 and its            ligands in tolerance and immunity. Annu Rev Immunol          2008;26: 677\u2013704.","DOI":"10.1146\/annurev.immunol.26.021607.090331"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Larkin,              J,                Chiarion-Sileni,              V, Gonzalez,                R, Grob,                JJ, Cowey,                CL, Lao,                CD, et al.            Combined nivolumab and ipilimumab or monotherapy in untreated            melanoma. N Engl J Med          2015;373: 23\u201334.","DOI":"10.1056\/NEJMoa1504030"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Tawbi,              HA, Burgess,                M,              Bolejack, V,                Van Tine,              BA, Schuetze,                SM, Hu,                J, et al.            Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028):            a multicentre, two-cohort, single-arm, open-label, phase 2 trial.            Lancet Oncol          2017;18: 1493\u2013501.","DOI":"10.1016\/S1470-2045(17)30624-1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Chen,              R, Zinzani,                PL, Fanale,                MA, Armand,                P, Johnson,                NA, Brice,                P, et al.            KEYNOTE-087Phase II study of the efficacy and            safety of pembrolizumab for relapsed\/refractory classic Hodgkin          lymphoma. J Clin Oncol          2017;35: 2125\u201332.","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Lettieri,                CK, Appel,                N, Labban,                N, Lussier,                DM,                Blattman,              JN,              Hingorani,            P. Progress and            opportunities for immune therapeutics in osteosarcoma.            Immunotherapy          2016;8: 1233\u201344.","DOI":"10.2217\/imt-2016-0048"},{"key":"29","doi-asserted-by":"crossref","first-page":"e27817","DOI":"10.4161\/onci.27817","volume":"3","year":"2014","unstructured":"29. Champiat,                S, Fert\u00e9,                C,                Lebel-Binay,              S, Eggermont,                A, Soria,                JC. Exomics            and immunogenics: Bridging mutational load and immune checkpoints            efficacy. OncoImmunology          2014;3: e27817.","journal-title":"OncoImmunology","ISSN":"https:\/\/id.crossref.org\/issn\/2162-4011","issn-type":"print"},{"key":"30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","year":"2014","unstructured":"30. Herbst,              RS, Soria,                JC,                Kowanetz,            M, Fine,                GD, Hamid,                O, Gordon,                MS, et al.            Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in            cancer patients. Nature          2014;515: 563\u20137.","journal-title":"?Nature","ISSN":"https:\/\/id.crossref.org\/issn\/0028-0836","issn-type":"print"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Snyder,              A, Makarov,                V,              Merghoub, T,                Yuan, J,                Zaretsky,              JM,                Desrichard,              A, et al.            Genetic basis for clinical response to CTLA-4 blockade in            melanoma. N Engl J Med          2014;371: 2189\u201399.","DOI":"10.1056\/NEJMoa1406498"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Snyder,              A, Wolchok,                JD, Chan,                TA. Genetic            basis for clinical response to CTLA-4 blockade. N Engl J            Med          2015;372: 783.","DOI":"10.1056\/NEJMc1415938"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Rizvi,              NA, Hellmann,                MD, Snyder,                A,                Kvistborg,              P, Makarov,                V, Havel,                JJ, et al.            Cancer immunology. Mutational landscape determines sensitivity to PD-1            blockade in non-small cell lung cancer. Science          2015;348: 124\u20138.","DOI":"10.1126\/science.aaa1348"},{"key":"34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","year":"2013","unstructured":"34. Lawrence,                MS,                Stojanov,            P, Polak,                P, Kryukov,                GV,                Cibulskis,              K,              Sivachenko,            A, et al.            Mutational heterogeneity in cancer and the search for new            cancer-associated genes. Nature          2013;499: 214\u20138.","journal-title":"?Nature","ISSN":"https:\/\/id.crossref.org\/issn\/0028-0836","issn-type":"print"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Shlien,              A, Campbell,                BB, de                Borja, R,                Alexandrov,              LB, Merico,                D, Wedge,                D, et al.            Biallelic Mismatch Repair Deficiency Consortium.            Combined hereditary and somatic mutations of replication error repair            genes result in rapid onset of ultra-hypermutated cancers. Nat            Genet          2015;47: 257\u201362.","DOI":"10.1038\/ng.3202"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Di                Giacomo, AM,                Biagioli,            M, Maio,                M. The            emerging toxicity profiles of anti-CTLA-4 antibodies across clinical            indications. Semin Oncol          2010;37: 499\u2013507.","DOI":"10.1053\/j.seminoncol.2010.09.007"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Attia,              P, Phan,                GQ, Maker,                AV,                Robinson,              MR, Quezado,                MM, Yang,                JC, et al.            Autoimmunity correlates with tumor regression in patients with metastatic            melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J            Clin Oncol          2005;23: 6043\u201353.","DOI":"10.1200\/JCO.2005.06.205"},{"key":"38","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","volume":"119","year":"2013","unstructured":"38. Weber,              JS, Dummer,                R, de Pril,                V, Lebb\u00e9,                C, Hodi,                FS, MDX010-20            Investigators. Patterns of onset and resolution of            immune-related adverse events of special interest with ipilimumab: detailed safety            analysis from a phase 3 trial in patients with advanced melanoma.            Cancer          2013;119: 1675\u201382.","journal-title":"Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Schubert,                D, Bode,                C,              Kenefeck, R,                Hou, TZ,                Wing, JB,                Kennedy, A,              et al. Autosomal dominant immune            dysregulation syndrome in humans with CTLA4 mutations. Nat            Med          2014;20: 1410\u20136.","DOI":"10.1038\/nm.3746"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Kotsa,              K, Watson,                PF,              Weetman,            APA. A CTLA-4            gene polymorphism is associated with both Graves disease and autoimmune            hypothyroidism. Clin Endocrinol (Oxf)          1997;46: 551\u20134.","DOI":"10.1046\/j.1365-2265.1997.1710996.x"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Iwama,              S, De              Remigis, A,                Callahan,              MK, Slovin,                SF,              Wolchok, JD,                Caturegli,              P. Pituitary            expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4            blocking antibody. Sci Transl Med          2014;6: 230ra45.","DOI":"10.1126\/scitranslmed.3008002"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Mitchell,                AL,              Cordell, HJ,                Soemedi, R,                Owen, K,                Skinningsrud,              B, Wolff,                AB, et al.            Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune            Addison\u2019s disease and Graves\u2019 disease susceptibility. J Clin            Endocrinol Metab          2009;94: 5139\u201345.","DOI":"10.1210\/jc.2009-1404"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Ansari,              MJ, Salama,                AD,              Chitnis, T,                Smith, RN,                Yagita, H,                Akiba, H,              et al. The programmed death-1 (PD-1)            pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice.            J Exp Med          2003;198: 63\u20139.","DOI":"10.1084\/jem.20022125"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Min,              L, Vaidya,                A, Becker,                C. Thyroid            autoimmunity and ophthalmopathy related to melanoma biological therapy.            Eur J Endocrinol          2011;164: 303\u20137.","DOI":"10.1530\/EJE-10-0833"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Torino,              F, Barnabei,                A, De                Vecchis, L,                Salvatori,              R, Corsello,                SM.            Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte            antigen 4: challenges from a new cause of a rare disease.            Oncologist          2012;17: 525\u201335.","DOI":"10.1634\/theoncologist.2011-0404"},{"key":"46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","volume":"19","year":"2016","unstructured":"46. Faje,              A.            Immunotherapy and hypophysitis: clinical presentation, treatment, and            biologic insights. Pituitary          2016;19: 82\u201392.","journal-title":"Pituitary","ISSN":"https:\/\/id.crossref.org\/issn\/1386-341X","issn-type":"print"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Byun,              DJ, Wolchok,                JD,                Rosenberg,              LM, Girotra,                M. Cancer            immunotherapy\u2014immune checkpoint blockade and associated          endocrinopathies. Nat Rev Endocrinol          2017;13: 195\u2013207.","DOI":"10.1038\/nrendo.2016.205"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Li,                L, Masood,                A, Bari,                S, Yavuz,                S,              Grosbach,            AB. Autoimmune            diabetes and thyroiditis complicating treatment with nivolumab.            Case Rep Oncol          2017;10: 230\u20134.","DOI":"10.1159\/000456540"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Godwin,              JL, Jaggi,                S,              Sirisena, I,                Sharda, P,                Rao, AD,                Mehra, R,              et al. Nivolumab-induced autoimmune            diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung            cancer. J Immunother Cancer          2017;5: 40.","DOI":"10.1186\/s40425-017-0245-2"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Hellmann,                MD, Rizvi,                NA,              Goldman, JW,                Gettinger,              SN, Borghaei,                H, Brahmer,                JR, et al.            Nivolumab plus ipilimumab as first-line treatment for advanced            non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1,            multicohort study. Lancet Oncol          2017;18: 31\u201341.","DOI":"10.1016\/S1470-2045(16)30624-6"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Eisenbarth,                GS,                Gottlieb,              PA. Autoimmune            polyendocrine syndromes. N Engl J Med          2004;350: 2068\u201379.","DOI":"10.1056\/NEJMra030158"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Kahaly,              GJ.            Polyglandular autoimmune syndromes. Eur J            Endocrinol          2009;161: 11\u201320.","DOI":"10.1530\/EJE-09-0044"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Kahaly,              GJ, Frommer,                L.            Polyglandular autoimmune syndromes. J Endocrinol            Invest          2018;41: 91\u20138.","DOI":"10.1007\/s40618-017-0740-9"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Maude,              SL, Frey,                N, Shaw,                PA, Aplenc,                R, Barrett,                DM, Bunin,                NJ, et al.            Chimeric antigen receptor T cells for sustained remissions in            leukemia. N Engl J Med          2014;371: 1507\u201317.","DOI":"10.1056\/NEJMoa1407222"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Lee,              DW,                Kochenderfer,              JN,                Stetler-Stevenson,              M, Cui,                YK,                Delbrook,            C, Feldman,                SA, et al.            T cells expressing CD19 chimeric antigen receptors for acute            lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation            trial. Lancet          2015;385: 517\u201328.","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Valle,              L, Vilar,                E,                Tavtigian,              SV, Stoffel,                EM. Genetic            predisposition to colorectal cancer: syndromes, genes, classification of genetic            variants and implications for precision medicine. J            Pathol          2019;247: 574\u201388.","DOI":"10.1002\/path.5229"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Stoffel,                EM, Mangu,                PB, Gruber,                SB,                Hamilton,              SR, Kalady,                MF, Lau,                MW, et al.            American Society of Clinical OncologyEuropean            Society of Clinical Oncology. Hereditary colorectal cancer            syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement            of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical            Practice Guidelines. J Clin Oncol          2015;33: 209\u201317.","DOI":"10.1200\/JCO.2014.58.1322"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Salman,              P, Panay,                S,                Fern\u00e1ndez,              R, Mahave,                M,                Soza-Ried,              C. Evidence of            response to pembrolizumab in a patient with Lynch syndrome-related metastatic colon            cancer. Onco Targets Ther          2018;11: 7295\u2013300.","DOI":"10.2147\/OTT.S167645"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Inthagard,                J, Edwards,                J,              Roseweir,            AK.            Immunotherapy: enhancing the efficacy of this promising therapeutic in            multiple cancers. Clinical Science          2019;133: 181\u2013193.","DOI":"10.1042\/CS20181003"}],"container-title":["Clinical Pediatric Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/28\/3\/28_2019-0006\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T23:41:52Z","timestamp":1563579712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/28\/3\/28_2019-0006\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1297\/cpe.28.59","relation":{},"ISSN":["0918-5739","1347-7358"],"issn-type":[{"value":"0918-5739","type":"print"},{"value":"1347-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}